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Abstract
Sterile or non-infectious inflammation and severe infection are
accompanied by very similar events. Damage (or danger)-
associated molecular patterns and pathogen-associated molecular
patterns trigger the release of inflammatory mediators and
modulate the expression of cell surface receptors. The increased
expression on monocytes and neutrophils of triggering receptor
expressed on myeloid cells 1 is a hallmark of both infectious and
non-infectious inflammation.
The report by Isibasi’s team published in the present issue of
Critical Care shows that the enhanced expression of
triggering receptor expressed on myeloid cells 1 (TREM-1) on
circulating monocytes in patients with acute pancreatitis is
independent of the occurrence of infection [1]. This study
further illustrates the difficulty of defining soluble or cell
surface markers that would allow delimiting a neat border
between infection and sterile or non-infectious inflammation.
The recently characterized damage (or danger)-associated
molecular patterns that emerged from the theory of danger
model proposed by Matzinger [2], and the pathogen-asso-
ciated molecular patterns that came to light after the revised
definition of innate immunity by Janeway [3], are the key
elements that unify infectious and non-infectious inflammation.
Indeed, the fact that the same Toll-like receptors (TLRs) and
NOD-like receptors recognize both damage (or danger)-
associated molecular patterns and pathogen-associated
molecular patterns explains how similar cascades of events
are occurring during inflammation independently of infection.
TREM-1 was first identified in sepsis [4], and its released
form (soluble TREM-1) has been long claimed as a marker of
infection [5]. Recent investigations, however, have shown
that soluble TREM-1 levels or TREM-1 membrane expression
is also enhanced in patients with non-infectious inflammatory
disorders, such as chronic obstructive pulmonary disease [6],
and in resuscitated patients after cardiac arrest [7] or after
cardiac or abdominal surgery [7,8]. TREM-1 is a key actor of
the inflammatory process. Anti-TREM-1 antibodies have been
used to mimic TREM-1 ligand, which remains to be fully
characterized. Not only do these antibodies activate
monocytes and neutrophils to produce cytokines [9], but they
also act in synergy with TLR4, TLR3, and NOD-like receptor
ligands [10,11]. TREM-1 surface expression is upregulated
by endotoxin [4] and NOD-like receptor ligands [11]. Since
endotoxin translocation has been reported in many different
clinical settings, including pancreatitis [12], one can suggest
in some of the non-infectious diseases that – in addition to
damage (or danger)-associated molecular patterns – endo-
toxin and some other pathogen-associated molecular patterns
could be responsible for the reported increased expression of
soluble TREM-1 or membrane TREM-1.
Ferat-Osorio and colleagues [1] complete the demonstration
by Wang and colleagues who had previously reported the
enhanced expression of TREM-1 mRNA in leukocytes of
patients with pancreatitis [13], and the report by Yasuda and
colleagues who showed enhanced levels of soluble TREM-1
in the same group of patients [14]. In these studies, TREM-1
mRNA expression and levels of circulating soluble TREM-1
were associated with the disease severity and organ
dysfunction. In contrast, the expression of TREM-1 on
monocytes was neither related to the severity of pancreatitis
nor to mortality [1]. A possible explanation is the inclusion of
only acute pancreatitis in Ferat-Osorio and colleagues’ study
while the study on mRNA also included mild pancreatitis. The
discrepancy with mRNA expression could be further
explained by post-transcriptional mechanisms, since an
upregulation of membrane expression was reported to occur
independently of mRNA synthesis [15]. Finally, another
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explanation may be that the analysis of mRNA was performed
on blood leukocytes, whereas that of its membrane
expression was investigated on monocytes.
Accordingly, it would be of great interest to investigate the
level of expression of TREM-1 on circulating neutrophils. The
discrepancy between monocyte surface expression and
soluble TREM-1 in terms of severity of the disease may reflect
the unknown respective contribution of neutrophils and
monocytes to the soluble form of TREM-1. As a function of
the severity of the pancreatitis, the release of the membrane
form of TREM-1 could reflect the level of its expression on the
surface of neutrophils. Alternatively, another possible mecha-
nism could be an enhanced release of the cell surface
expression of TREM-1 from monocytes as a reflection of the
severity of acute pancreatitis, while the enhanced mRNA
expression sustains an enhanced level of cell surface
expression. Ferat-Osorio and colleagues also studied other
parameters that are known to be upregulated during
inflammation, such as IL-6 and IL-10, or to be downregulated,
such as the expression of HLA-DR on monocytes [1].
Interestingly, and in contrast with membrane TREM-1, these
makers could allow discriminating between mild and severe
acute pancreatitis.
In conclusion, the study of Isibasi’s team further illustrates the
overlapping processes during infectious and non-infectious
inflammation, and demonstrates for the first time the en-
hanced expression of TREM-1 on the surface of monocytes in
pancreatitis [1]. It remains to be demonstrated whether the
TREM-1 ligand is present in plasma of these patients or is
expressed on the surface of other cells – in order to conclude
on the key role played by membrane TREM-1 during acute
pancreatitis, contributing to the systemic inflammatory
response syndrome that characterizes this disease.
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